Cargando…

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J.-P., Bokemeyer, C., Curran, D., Gross, A., Vermorken, J. B.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946862/ https://www.ncbi.nlm.nih.gov/pubmed/20335368 http://dx.doi.org/10.1093/annonc/mdq077

Ejemplares similares

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
por: Licitra, L., et al.
Publicado: (2011)

Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report
por: Mesía, Ricard, et al.
Publicado: (2010)

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)
por: Seiwert, T. Y., et al.
Publicado: (2014)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
por: Vermorken, J. B., et al.
Publicado: (2014)

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
por: Vermorken, J. B., et al.
Publicado: (2014)

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
por: Vermorken, J B, et al.
Publicado: (2011)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
por: del Campo, J M, et al.
Publicado: (2011)

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
por: Balin-Gauthier, D, et al.
Publicado: (2008)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
por: Cavalieri, Stefano, et al.
Publicado: (2022)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment
por: Galbiati, Donata, et al.
Publicado: (2019)

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study
por: Klinghammer, K., et al.
Publicado: (2021)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009)

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen
por: Soulières, Denis, et al.
Publicado: (2016)

Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution
por: de Mello, Ramon Andrade, et al.
Publicado: (2014)

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
por: Berger, Bernhard, et al.
Publicado: (2008)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
por: Hannouf, Malek B., et al.
Publicado: (2012)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
por: Borel, Christian, et al.
Publicado: (2018)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
por: Yoshino, Takayuki, et al.
Publicado: (2013)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and Neck()
por: de Llobet, Lara I., et al.
Publicado: (2014)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
por: Hecht, Markus, et al.
Publicado: (2021)

Gemcitabine Plus Platinum versus Docetaxel Plus Platinum as First-Line Therapy for Metastatic Nasopharyngeal Carcinoma: A Randomized Clinical Study
por: Yang, Hui, et al.
Publicado: (2021)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Homologous platelet gel on radiation-induced dermatitis in a patient receiving head and neck radiotherapy plus cetuximab: A case report
por: Guberti, Monica, et al.
Publicado: (2023)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
por: Guigay, Joël, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cav1cqfth34tgo6i8fpdgu9fk3